- Flu vaccine efficacy claims are inflated by flawed study designs and unadjusted confounding biases.
- CDC’s VISION network reports show inconsistent, untrustworthy data across five flu seasons, with half of estimates showing “pseudo-randomization” and the other half “negative confounding.”
- Peer-reviewed studies, including the Cochrane Collaboration and Lisa Jackson’s research, confirm observational studies overstate vaccine benefits due to the “healthy vaccinee effect.”
- Flu-related deaths are vastly overestimated by CDC, while adverse event reports (VAERS) reveal over 1,000 deaths and 1,600 cases of Guillain-Barré Syndrome linked to vaccines.
- Conflict of interest permeates vaccine promotion, with regulatory agencies like the CDC and FDA captured by pharmaceutical industry interests.
- Natural immunity and alternatives like vitamin D supplementation are safer, more effective, and scientifically supported.
The VISION Network’s Data Paradox
The CDC’s VISION network, tasked with measuring flu vaccine effectiveness, has produced results so contradictory that even its own researchers admit to “pseudo-randomization” and “negative confounding.” Between 2021 and 2026, 12 estimates of flu vaccine efficacy for the elderly showed no consistent pattern. In some seasons, adjusted effectiveness barely budged after statistical corrections (e.g., 31% to 29%), while in others, adjustment increased estimated effectiveness by over 20 percentage points in hospital settings. This inconsistency defies the principles of observational study design, where confounding factors like the “healthy vaccinee effect” should reduce apparent efficacy. Instead, the data suggests either miraculous pseudo-randomization or systemic methodological flaws.
Lisa Jackson’s team at Group Health in Seattle followed more than 72,000 people aged 65 and older over eight years. Their trick was elegant: they measured the “vaccine effect” in periods when flu isn’t circulating, where a true vaccine effect should be zero.
The relative risk of death for vaccinated versus unvaccinated seniors was 0.39 before flu season, 0.56 during, and 0.74 after. A vaccine cannot prevent deaths from a virus that isn’t circulating, so the pre-season benefit is the signature of healthier people choosing to get vaccinated. The authors concluded the bias was large enough to account entirely for the associations seen during flu season, and that adjusting for diagnosis-code variables did not remove it. This corroborates Shahar’s premise strongly: observational estimates in the elderly can be driven by who gets vaccinated rather than by what the vaccine does.
The healthy vaccinee effect (where healthier, more health-conscious individuals are more likely to vaccinate) creates a bias that inflates vaccine effectiveness. Adjusting for this should shrink efficacy estimates. Yet in the VISION reports, adjustments often amplified results, a phenomenon known as “negative confounding.” This contradiction raises urgent questions: Are the CDC’s flu vaccine claims based on rigorous science, or are they a product of a system designed to prioritize profit over public health?
The Marketing of a Myth
Peter Doshi, a Johns Hopkins scientist, exposed the CDC’s messaging as a “marketing disease” campaign in his 2013 BMJ analysis. He highlighted how flu is often conflated with “influenza-like illness,” inflating perceived vaccine efficacy. Meanwhile, CDC statistics on flu deaths have shifted dramatically. In 2003, they claimed 36,000 annual U.S. deaths from flu, but by 2012, they admitted only 8.5% of pneumonia/influenza deaths were directly linked. This revision, paired with VAERS data showing 84,000 adverse reactions (including 1,000 deaths) from 2009–2020, paints a picture of a public health agency more interested in promoting vaccines than ensuring safety.
Doshi argues that the vaccine’s growth was driven by a public health campaign delivering a simple message: flu is serious, everyone is at risk, the shot is nearly risk-free, and vaccination saves lives. His critique was that the evidence underneath that message was weaker than the message implied.
His sharpest point is found in the arithmetic. Some observational studies implied vaccines prevent about 50% of all-cause deaths, while flu is estimated to cause only around 5% of winter deaths. That is too good to be true, which is exactly the healthy-vaccinee problem Jackson measured. He also argued that “flu” and “influenza” are used interchangeably, though only a fraction of flu-like illness is actually influenza, which helps explain why many people feel the shot doesn’t work. He characterized this as disease mongering: expanding a market by broadening how people perceive a threat.
The fraud here is pervasive because the financial stakes are staggering. The global flu vaccine market is projected to exceed $6 billion by 2028, with pharmaceutical giants like Pfizer and Moderna reaping profits while regulatory agencies like the FDA and CDC remain under industry influence. A 2006 Cochrane review found no evidence flu vaccines prevent the flu in children under two, and a 2022 analysis of 64 studies concluded vaccines offer little to no protection for the elderly. Yet the CDC persists in its messaging, despite its own data revealing a 1.5% efficacy rate in adults.
The flu vaccine controversy is part of a broader pattern of regulatory capture and public health deception. The CDC’s ties to Big Pharma are well-documented: former agency leaders hold shares in vaccine manufacturers, and clinical trials are often funded by the companies selling the vaccines. This conflict of interest extends to mandatory vaccination policies, which face growing resistance as the public becomes aware of the risks.
Therein, the flu vaccine saga showcases a deeper crisis in public health: the erosion of informed consent and the prioritization of corporate profits over scientific integrity. As Dr. Tom Jefferson of the Cochrane Collaboration argues, cost-effective alternatives like vitamin D supplementation and hygiene measures are underemphasized while dangerous, unproven vaccines are mandated. The next flu season may bring another round of false promises, but with awareness growing, the public can no longer be so easily misled.
Sources include:
Please contact us for more information.